The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Jeffrey Heier discuss inhibition of angiopoietin-2 and its potential effect on current treatment paradigms for the management of neovascular age-related macular degeneration.

The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. In this podcast, Dr. Carl Regillo and Dr. Charles Wykoff discuss emerging drug delivery systems for the management of neovascular retinal disease.

In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Arshad M. Khanani, MD, MA, discuss new findings about emerging therapies that target the angiopoietin/Tie2 pathway that may improve the treatment of neovascular retinal diseases.

Transcript: https://bit.ly/38jWicU

To obtain CME Credit, please go here: https://bit.ly/2nBqmhq 

In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Nancy M. Holekamp, MD, discuss delivery systems for neovascular retinal diseases, with a particular focus on age-related macular degeneration.

Transcript: https://bit.ly/2PqSj5P

To obtain CME credit, please go here: https://bit.ly/2mNmJVt

In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Nathan C. Steinle, MD, discuss dosing strategies in patients with neovascular age-related macular degeneration (AMD) to help improve patient outcomes.

Transcript: https://bit.ly/2DZw9SC

To obtain CME credit, please go here: https://bit.ly/2ombOmh

In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Theodore Leng MD, MS, discuss the burden of treatment on patients with neovascular age-related macular degeneration (AMD) and strategies for overcoming barriers to treatment. 

Transcript: https://bit.ly/2YB3q0e

To obtain CME Credit, please go here: https://bit.ly/2ojxBec 

In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Dilsher S. Dhoot, MD, discuss current barriers to care of patients with neovascular age-related macular degeneration (AMD) and other management considerations for providers. 

Transcript: https://bit.ly/2RL41uX

To obtain CME Credit, please go here: https://bit.ly/2mJfo9s

In this MedEdTalks micro-CE podcast, Rishi P. Singh, MD, and Andrew A. Moshfeghi, MD, MBA, will discuss current insights and the evidence-based use of anti-vascular epithelial growth factor (VEGF) in diabetic retinopathy. 

Transcript: https://bit.ly/3542h3r

To obtain CME credit, please go here: https://bit.ly/2ojW0QQ

In this podcast series Dr. Rishi Singh will be talking with:

• Dr. Andrew Moshfeghi on Current Insights into Anti-VEGF use in Diabetic Retinopathy;
• Dr. Dilsher Dhoot on how to address the treatment burden in nAMD as a provider;
• Dr. Ted Leng on how to address the treatment burden in nAMD with patients;
• Dr. Nathan Steinle on real world applications for dosing strategies in nAMD;
• Dr. Nancy Holekamp on drug delivery in neovascular retinal disease; and with
• Dr. Arshad Khanani on targeting treatment in neovascular retinal disease

We encourage you to take 12 to 15 minutes out of your day to hear these updates on neovascular retinal diseases